查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1727073

妊娠高血壓腎臟病診斷的全球市場 - 市場考察，競爭情形，市場預測(2032年)

Preeclampsia Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

預計在 2025-2032 年預測期內，全球子癇前症診斷市場規模將以 3.67% 的複合年增長率成長。市場成長主要源自於子癇前症及其相關風險因素的盛行率不斷上升，以及孕婦和醫護人員對此疾病認知度的不斷提升。此外，預計在 2025-2032 年預測期內，主要市場參與者持續的產品開發活動將進一步促進市場擴張。

子癇前症診斷市場動態

全球先兆子癇盛行率的不斷上升，正在顯著推動整個子癇前症診斷市場的發展。根據世界衛生組織 (WHO) (2024) 的數據，子癇前症影響全球 2-8% 的懷孕。這種妊娠相關併發症的特徵是高血壓和器官損害，主要發生在妊娠20週後，許多女性都會面臨這種情況，因此對早期和準確檢測方法的需求正在穩步增長。

此外，英國產科監測系統 (UKOSS) 的一項研究發現，嚴重肥胖患者的子癇前症盛行率為 9%，而非肥胖對照組的盛行率為 2%。此外，根據子癇前症基金會 (2024) 提供的數據，妊娠高血壓疾病 (HDP)，包括妊娠高血壓、慢性高血壓、子癇前症和子癇等疾病，影響全球約 5-10% 的懷孕。

子癇前症是 HDP 的主要和最嚴重的形式，通常以血壓升高和器官系統（尤其是肝臟和腎臟）受損的跡象為特徵。由於妊娠期子癇（HDP）持續構成重大健康風險，預計全球先進子癇前症診斷技術的採用將持續增加。孕產婦年齡增長、肥胖、糖尿病、高血壓和多胎妊娠等因素是增加子癇前症風險的主要因素。因此，全球子癇前症患者數量正在增加，預計將推動子癇前症診斷市場的成長。

提高孕婦的認知度也是子癇前症診斷市場的主要成長動力。例如，為了紀念2025年1月23日的孕產婦健康宣傳日，先兆子癇基金會與 "病患與目標" （Patients & Purpose）組織合作，發起了GAP-SPIRIN活動。這項實證教育倡議旨在推廣使用低劑量阿斯匹靈預防子癇前症，並解決孕產婦健康差距問題。

該活動結合了黑人孕婦面臨的獨特課題資訊和低劑量阿斯匹靈預防指南，幫助醫療保健提供者更好地管理子癇前症的風險。子癇前症是一種嚴重的、可能危及生命的妊娠期和產後高血壓疾病。它是孕產婦健康危機的核心問題，對黑人母親的影響尤其嚴重，發生率高達 60%。

市場主要參與者開發的創新診斷測試正在顯著促進市場成長。 2022 年 5 月，Mirvie 宣布其 Mirvie 子癇前症測試獲得美國 FDA 突破性設備稱號。這項突破性的測試旨在在症狀出現之前對女性患有子癇前症的風險進行個別評估。此檢測由專有的 Mirvie RNA 平台提供，可分析每個妊娠特有的生物訊號，預測不可預見的併發症風險，從而實現更早、更個人化的臨床幹預。

儘管存在這些充滿希望的成長動力，但子癇前症診斷市場仍面臨課題。患者和醫療保健提供者的認知度有限，以及子癇前症診斷測試​​準確性的局限性，都是可能在預測期內阻礙市場成長的重大阻礙因素。

本報告研究了全球子癇前症診斷市場，並提供了市場規模和預測、過去三年產品/技術發展、市場主要參與者以及可用機會等資訊。

本報告提供全球妊娠高血壓腎臟病診斷市場相關調查分析，提供市場規模與預測，過去3年的產品/技術開發，市場主要企業，可利用的機會等資訊。

目錄

第1章 妊娠高血壓腎臟病診斷市場報告的簡介

第2章 妊娠高血壓腎臟病診斷市場摘要整理

  • 市場概要

第3章 競爭情形

第4章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 妊娠高血壓腎臟病診斷市場主要原因的分析

  • 妊娠高血壓腎臟病診斷市場促進因素
  • 妊娠高血壓腎臟病診斷市場阻礙因素與課題
  • 妊娠高血壓腎臟病診斷市場機會

第6章 妊娠高血壓腎臟病診斷市場上波特的五力分析

第7章 妊娠高血壓腎臟病診斷市場評估

  • 檢體類別
    • 血液檢驗
    • 尿液檢查
  • 各產品類型
    • 試劑·套件
    • 器具
  • 檢驗方式
    • 實驗室為基礎的檢驗
    • 就地檢驗(POCT)
  • 各終端用戶
    • 醫院
    • 專門診所
    • 診斷中心
    • 其他
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 妊娠高血壓腎臟病診斷市場企業與產品的簡介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Labcorp
  • PerkinElmer
  • ARUP Laboratories
  • Siemens Healthineers AG
  • QuidelOrtho Corporation
  • Revvity
  • Randox Laboratories
  • CERCA Biotech

第9章 KOL的見解

第10章 計劃方法

第11章 關於DelveInsight

第12章 免責聲明，諮詢方式

Product Code: DIMDCL0862

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of preeclampsia worldwide & associated risk factors and growing awareness among pregnant women and healthcare professionals

The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032. The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

Preeclampsia Diagnostics Market Dynamics:

The rising prevalence of preeclampsia globally is significantly boosting the overall market for preeclampsia diagnostics. According to the data provided by the World Health Organization (2024), preeclampsia affects 2-8% of pregnancies worldwide. As more women face this pregnancy-related complication, primarily marked by high blood pressure and signs of organ damage usually occurring after the 20th week of gestation, the need for early and accurate detection methods is steadily increasing.

Additionally, the UK Obstetric Surveillance System (UKOSS) study showed an incidence of preeclampsia of 9% in severely obese patients compared to 2% of nonobese controls. Also, according to the data provided by the Preeclampsia Foundation Organization (2024), hypertensive disorders of pregnancy (HDPs), which include conditions such as gestational hypertension, chronic hypertension, preeclampsia, and eclampsia, affected approximately 5-10% of all pregnancies worldwide.

Preeclampsia is a major and most severe form of HDP, often characterized by elevated blood pressure and signs of damage to organ systems, particularly the liver and kidneys. As HDPs continue to pose significant health risks, the adoption of advanced preeclampsia diagnostic technologies is expected to boost across the globe. Factors such as increasing maternal age, obesity, diabetes, hypertension, and multiple pregnancies are key contributors to the growing risk of developing preeclampsia. Therefore, the rising cases of preeclampsia across the globe are expected to boost the growth of the preeclampsia diagnostics market.

Increasing awareness among pregnant women is another key factor driving the growth of the preeclampsia diagnostics market. For example, in January 2025, in recognition of Maternal Health Awareness Day on January 23rd, the Preeclampsia Foundation, in collaboration with Patients & Purpose, launched the "GAP-SPIRIN" campaign. This evidence-based educational initiative promotes the use of low-dose aspirin to help prevent preeclampsia and address disparities in maternal health.

The campaign combines information on the unique challenges faced by Black expectant mothers with guidance on low-dose aspirin prophylaxis, equipping healthcare providers to better manage preeclampsia risk. Preeclampsia is a severe hypertensive condition that can pose life-threatening risks during pregnancy and the postpartum period. It is a central issue in the maternal health crisis, disproportionately affecting Black mothers, who are 60% more likely to develop the condition.

The development of innovative diagnostic tests by key market players is significantly contributing to market growth. A notable example is Mirvie, which in May 2022 announced it received U.S. FDA Breakthrough Device designation for its Mirvie Preeclampsia Test. This groundbreaking test is designed to assess a woman's individualized risk of developing preeclampsia before symptoms arise. It is powered by the proprietary Mirvie RNA platform, which analyzes the unique biological signals of each pregnancy to predict the risk of unexpected complications enabling earlier and more personalized clinical intervention.

Despite these promising growth factors, the preeclampsia diagnostics market faces challenges. Limited awareness among patients and providers and limitations in the accuracy of preeclampsia diagnostic tests are significant constraints that could potentially hinder market growth during the forecast period.

Preeclampsia Diagnostics Market Segment Analysis:

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits, and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the sample type segment of the preeclampsia diagnostics market, the blood test category held the largest revenue share in 2024. The growth of this category is attributed to the rising use of blood tests in preeclampsia diagnostics. These tests are playing a transformative role by enabling earlier, more accurate, and accessible detection of preeclampsia even before clinical symptoms manifest. Their ability to identify risk at an early stage allows for timely intervention, significantly improving maternal and fetal outcomes.

These tests provide precise risk stratification, helping clinicians predict which patients are more likely to develop severe preeclampsia. This capability supports the efficient use of hospital resources, minimizes unnecessary interventions, and enhances patient care. Moreover, blood-based diagnostics are highly scalable and easily integrated into routine prenatal care. As awareness of preeclampsia continues to grow, and as point-of-care testing becomes more accessible even in low-resource settings the demand for these tests is expected to increase.

A major advancement in this space is the development of biomarker-based blood tests, particularly those that measure levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). These biomarkers allow healthcare providers to detect preeclampsia in its early or asymptomatic stages, offering a critical tool for proactive, personalized pregnancy management.

Recent innovations in molecular diagnostics and immunoassays have led to the development of advanced blood tests for preeclampsia. For instance, companies like Thermo Fisher Scientific, PerkinElmer, and Roche Diagnostics offer blood test-based platforms for preeclampsia detection. For instance, in May 2023, the U.S. FDA approved Thermo Scientific B*R*A*H*M*S PlGF plus KRYPTOR and B*R*A*H*M*S sFlt-1 KRYPTOR novel blood-based biomarker test for the risk assessment and clinical management of preeclampsia.

Thus, all these factors are fueling the adoption of blood tests, thereby acting as a strong catalyst in the growth of the blood-based preeclampsia test, thereby driving the overall expansion of the preeclampsia diagnostics market.

North America is expected to dominate the overall Preeclampsia Diagnostics Market:

North America is projected to account for the largest share of the preeclampsia diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

According to the recent data provided by the Centre for Disease Control and Prevention (2022), preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies in the US. Additionally, as per the same source, in the United States, the rate of preeclampsia in Black women is 60 percent higher than in White women.

Given the serious health risks it poses to both mother and baby, including preterm birth, placental abruption, and even maternal or fetal death, healthcare providers are placing increased emphasis on early screening and continuous monitoring thereby boosting the overall market of preeclampsia diagnostics across the region.

Moreover, growing product development activities among the key market players are likely to propel the revenue shares for the preeclampsia in the region. For example, In January 2024, Labcorp, a global leader in innovative and comprehensive laboratory services, announced the launch and availability of a new FDA-cleared blood test designed for the risk assessment and clinical management of severe preeclampsia, a potentially life-threatening blood pressure disorder that can occur during pregnancy and the postpartum period.

Preeclampsia Diagnostics Market Key Players:

Some of the key market players operating in the Preeclampsia Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

Recent Developmental Activities in the Preeclampsia Diagnostics Market:

  • In February 2025, Roche announced that its Elecsys(R) sFlt-1/PlGF ratio test for preeclampsia received 510(k) clearance from the U.S. FDA. The test was intended to stratify hospitalized pregnant women with hypertensive disorders into low- and high-risk groups for developing severe preeclampsia within two weeks. This enabled better prediction, earlier interventions, and reduced adverse outcomes.
  • In May 2024, Labcorp launched its first-trimester preeclampsia screening test, designed to be performed between 11 and 14 weeks of gestation to assess the risk of developing preeclampsia before 34 weeks. It was the only test of its kind available in the U.S. and applied to all pregnant individuals, including those with low- to average-risk or first-time pregnancies.

Key Takeaways from the Preeclampsia Diagnostics Market Report Study

  • Market size analysis for current preeclampsia diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the preeclampsia diagnostics market
  • Various opportunities available for the other competitors in the preeclampsia diagnostics market space
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current preeclampsia diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for preeclampsia diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Preeclampsia Diagnostics Market Report Study

  • Preeclampsia diagnostics product providers
  • Research organizations and consulting companies
  • Preeclampsia diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in preeclampsia diagnostics
  • Various end-users who want to know more about the preeclampsia diagnostics market and the latest technological developments in the preeclampsia diagnostics market

Frequently Asked Questions for the Preeclampsia Diagnostics Market:

1. What are Preeclampsia Diagnostics?

  • Preeclampsia diagnostics refers to the methods and tools used to detect preeclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to other organs, often the liver and kidneys. Diagnostics typically involve blood pressure monitoring, urine protein tests, and biomarker-based blood tests (e.g., sFlt-1/PlGF ratio) to assess the risk, presence, or severity of the condition.

2. What is the market for Preeclampsia Diagnostics Market?

  • The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032.

3. What are the drivers for the global Preeclampsia Diagnostics Market?

  • The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Preeclampsia Diagnostics Market?

  • Some of the key market players operating in the preeclampsia diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

5. Which region has the highest share in the global Preeclampsia Diagnostics Market?

  • North America is expected to dominate the overall preeclampsia diagnostics market during the forecast period, 2025 to 2032. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

Table of Contents

1. Preeclampsia Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Preeclampsia Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Preeclampsia Diagnostics Market Key Factors Analysis

  • 5.1. Preeclampsia Diagnostics Market Drivers
    • 5.1.1. Rising cases of preeclampsia and associated risk factors
    • 5.1.2. Rising awareness among pregnant women and healthcare professionals
    • 5.1.3. Growing product development activities among the key market players
  • 5.2. Preeclampsia Diagnostics Market Restraints and Challenges
    • 5.2.1. Limited awareness among patients and providers
    • 5.2.2. Limitations in the accuracy of preeclampsia diagnostic tests
  • 5.3. Preeclampsia Diagnostics Market Opportunities
    • 5.3.1. Ongoing research into novel biomarkers-based preeclampsia testing and home-based testing

6. Preeclampsia Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Preeclampsia Diagnostics Market Assessment

  • 7.1. By Sample Type
    • 7.1.1. Blood Test
    • 7.1.2. Urine Test
  • 7.2. By Product Type
    • 7.2.1. Reagents & Kits
    • 7.2.2. Instruments
  • 7.3. Mode of Testing
    • 7.3.1. Laboratory-based Testing
    • 7.3.2. Point-of-care Testing (POCT)
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Diagnostic Centers
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.3. India Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Preeclampsia Diagnostics Market Size in USD million (2022-2032)

8. Preeclampsia Diagnostics Market Company and Product Profiles

  • 8.1. F. Hoffmann-La Roche Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Thermo Fisher Scientific Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Labcorp
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. PerkinElmer
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. ARUP Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Siemens Healthineers AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. QuidelOrtho Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Revvity
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Randox Laboratories
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. CERCA Biotech
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Preeclampsia Diagnostics Market in Global (2022-2032)
  • Table 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
  • Table 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
  • Table 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
  • Table 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
  • Table 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
  • Table 8: Preeclampsia Diagnostics Market in North America (2022-2032)
  • Table 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
  • Table 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
  • Table 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
  • Table 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
  • Table 13: Preeclampsia Diagnostics Market in France (2022-2032)
  • Table 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
  • Table 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
  • Table 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
  • Table 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
  • Table 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 20: Preeclampsia Diagnostics Market in China (2022-2032)
  • Table 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
  • Table 22: Preeclampsia Diagnostics Market in India (2022-2032)
  • Table 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
  • Table 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
  • Table 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
  • Table 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
  • Table 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
  • Table 29: Preeclampsia Diagnostics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Preeclampsia Diagnostics Market in Global (2022-2032)
  • Figure 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
  • Figure 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
  • Figure 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
  • Figure 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
  • Figure 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
  • Figure 8: Preeclampsia Diagnostics Market in North America (2022-2032)
  • Figure 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
  • Figure 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
  • Figure 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
  • Figure 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
  • Figure 13: Preeclampsia Diagnostics Market in France (2022-2032)
  • Figure 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
  • Figure 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
  • Figure 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
  • Figure 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
  • Figure 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
  • Figure 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
  • Figure 20: Preeclampsia Diagnostics Market in China (2022-2032)
  • Figure 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
  • Figure 22: Preeclampsia Diagnostics Market in India (2022-2032)
  • Figure 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
  • Figure 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
  • Figure 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
  • Figure 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
  • Figure 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
  • Figure 29: Preeclampsia Diagnostics Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis